Van ECK Associates Corp Sells 9,853 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Van ECK Associates Corp lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 13.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 61,233 shares of the biopharmaceutical company's stock after selling 9,853 shares during the quarter. Van ECK Associates Corp's holdings in Alnylam Pharmaceuticals were worth $11,721,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ALNY. Quent Capital LLC increased its holdings in shares of Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 123 shares during the last quarter. Anchor Investment Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $38,000. GAMMA Investing LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $52,000. Lindbrook Capital LLC increased its position in shares of Alnylam Pharmaceuticals by 37.2% during the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 100 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in Alnylam Pharmaceuticals by 52.4% in the third quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company's stock valued at $160,000 after buying an additional 311 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. StockNews.com raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Monday. The Goldman Sachs Group cut Alnylam Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $230.00 to $173.00 in a research note on Friday, February 16th. Royal Bank of Canada restated an "outperform" rating and set a $235.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Citigroup decreased their target price on Alnylam Pharmaceuticals from $237.00 to $227.00 and set a "buy" rating on the stock in a research note on Friday, February 16th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $395.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $215.88.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY traded up $2.02 during mid-day trading on Friday, reaching $152.33. The company's stock had a trading volume of 452,157 shares, compared to its average volume of 763,489. The stock has a market cap of $19.19 billion, a P/E ratio of -42.22 and a beta of 0.41. The company's fifty day simple moving average is $149.76 and its two-hundred day simple moving average is $165.25. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. Alnylam Pharmaceuticals's revenue was up 54.8% on a year-over-year basis. During the same period in the prior year, the business posted ($1.40) earnings per share. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -4.46 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.